Wow, up 24% in one day; over 57 % from the low.

Go IPIX

Farrell

Exciting news which will lead to more information relatively soon.

GLTA, Farrell

Thanks for posting and reminding us of the early PMX research on Brilacidin which confirmed its anti fungal qualities.

GLTA Farrell

Nice find again. Thanks

I thought this comment was interesting,too.

"Today we're only spending exploration capex in São Tomé and Namibia. By 2025, if not before
that, we will know a lot more about these two assets."

From the transcript:

https://www.galp.com/corp/Portals/0/Recursos/Investidores/4Q_Results_2022/4Q22%20Presentation%20Transcript.pdf

Farrell

On a more positive note, IPIX reported $238,000 for “reimbursement for Brilacidin manufacturing expenses”.

Good find...Alpha Sigma did report they are making plans for a Stage 2 trial.

From the last 10Q:

"Phase 1 studies in healthy volunteers using Brilacidin in a proprietary Alfasigma formulation have successfully completed, and Alfasigma notified the Company in late September 2022 that a Phase 2 multinational clinical trial is estimated to start in 2H2023. "

The other possibility is Brilacin for OM, additional viral or fungal research, but no announcements have been made about a partner for stage 3 OM trial.

Interesting the price ticked up on increased volume after a lackluster 10 Q

GLTA, Farrell

Clinical trials .gov shows 23 studies using some type of nasal spray. Most of these are repurposed approved steroid inhalers , but the list include hydroxychloroquine, one antiviral, thyme oil , heparin and other investigational drugs.

May be Brilacidin will get a shot.

Time will tell,

GLTA, Farrell

Who knows, perhaps the Brilacidin nasal swab and nasal spray could shake out a partner to fund a clinical trial for both against a placebo control.

BTW did you notice the contents of the nasal spray in the article you posted?. It looks like the ingredients for a middle eastern dish. I was expecting an antiviral pharmaceutical.

Thanks for posting

Farrell

Full article from 2021 describing swab system for treatment of early Covid 19. I could find no mention of Brilacidin in this article, but he seemed to believe Brilacidin was important enough to mention it in his patent along with articles from the early research of brilacidin.

The patent application specifically references this article:

Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture
by Allison Bakovic
1, Kenneth Risner
1 [ORCID] , Nishank Bhalla
1, Farhang Alem
1 [ORCID] , Theresa L. Chang
2 [ORCID] , Warren K. Weston
3, Jane A. Harness
3 and Aarthi Narayanan

https://www.americanpharmaceuticalreview.com/Featured-Articles/584544-Simple-and-Economical-Multifunctional-Therapeutic-Swab-Device-System-for-Treating-Upper-Respiratory-Infections-Including-COVID-19-on-a-Mass-Scale/

https://www.mdpi.com/1999-4915/13/2/271

More on Subhash Dhawab:

Experience

BIOMEDICAL SCIENTIST (INDEPENDENT) Graphic
Senior FDA Research & Regulatory Scientist (Retired)
BIOMEDICAL SCIENTIST (INDEPENDENT)

Jan 2019 - Present4 years 2 months

United States

• Independent science writer
• Invited reviewer of manuscripts for peer-reviewed scientific journals
• Can provide guidance on research and regulatory projects related to in vitro diagnostics, vaccines, and therapeutics
• Can provide short-term or long-term contractual and consulting services for advancing research and regulatory projects
• Can provide editorial assistance

Published six articles and filed a patent application (U.S. and PCT Patent Pending) after retiring from the US FDA in December 2018

FDA Graphic
Senior FDA Research & Regulatory Scientist
FDA

Apr 1993 - Dec 201825 years 9 months

United States

Senior Investigator and Chief, Viral Immunology Section, Laboratory of Molecular Virology

Laboratory Research:

• Directed a comprehensive research program to conduct investigation on HIV-1 and other viruses, including Ebola, Zika, and poxvirus. Other administrative responsibilities included planning, coordinating research with outside collaborators, management, and supervision of research fellows and students.

Product Regulation:

• Provided guidance and…
Department of Cellular Immunology, Walter Reed Army Institute of Research, Washington, D.C. Graphic
Senior National Research Council Associate
Department of Cellular Immunology, Walter Reed Army Institute of Research, Washington, D.C.

Apr 1991 - Mar 19932 years

United States

Investigated HIV-1 pathogenesis regarding how HIV infection is localized to the peripheral and central nervous systems. The major outcome of this highly productive research program revealing marked invasiveness by HIV-infected macrophages defined a previously unknown mechanism for facilitating their escape from the vascular system. These studies yielded a novel experimental modality for designing therapeutic strategies to retard the progression of HIV infection.
Departments of Biochemistry and Pharmacology, Georgetown University Medical Center, Washington, D.C. Graphic
Research Associate (1984-1986)/Research Assistant Professor (1990-1991)
Departments of Biochemistry and Pharmacology, Georgetown University Medical Center, Washington, D.C.

1984 - 19917 years

United States

Work focused on understanding the biochemical and pharmacologic aspects of the neuronal nicotinic receptors which influence the function of nearly all peripheral organs. The major outcome of this work revealed varying distribution of high affinity nicotinic receptors, indicative of the differential sensory functions in the central nervous system, and provided valuable insights into the regulation of nicotinic receptors and in developing new therapeutic modalities for treating neurological…

National Institute of Dental Research, National Institutes of Health, Bethesda, MD Graphic
Senior Staff Fellow
National Institute of Dental Research, National Institutes of Health, Bethesda, MD

Apr 1987 - Apr 19903 years 1 month

United States

Developed a method to identify HTLV-I-binding cell types in heterogeneous leukocyte populations. This work discovered B cells, in addition to T cells, as a new target for HTLV-I infection and provided future directions for evaluating HTLV-I pathogenesis.
Department of Physiology, Duke University Medical Center, Durham, NC Graphic
Research Associate
Department of Physiology, Duke University Medical Center, Durham, NC

Jun 1982 - Dec 19831 year 7 months

United States

Studies focused on the assembly of the low-density lipoprotein (LDL) with particular emphasis on its differential capacity to bind various lipids. These studies provided useful insights into the understanding of the mechanism for apo-LDL interaction with its two major lipid counterparts -- cholesterol and phospholipid -- in defining its role in hyperlipidemic-related cardiovascular disorders.

Education

Central Drug Research Institute, Lucknow, India Graphic
Central Drug Research Institute, Lucknow, India
Ph.D.Biomedical research

1977 - 1981

Publications

Dhawan, S. Is COVID-19 mRNA Vaccination Safe in HIV-1 and Other Retroviral Infections? Am. Pharma. Rev. (Published on December 22, 2022)
American Pharmaceutical Review December 22, 2022

ABSTRACT: Translocation from the cytoplasm to nucleus and integration of reverse-transcribed SARS-CoV-2 spike mRNA into the genomic DNA of COVID-19 mRNA-vaccinated individuals positive for HIV-1 or other retroviral infections HIV-1 or other retroviral infections raise a possibility of generation of a new type of retrovirus. Such retrovirus expressing both HIV-1 receptor-binding domain (gp120) and SARS-CoV-2 receptor-binding domain (SARS-CoV-2-spike protein) could not only have the potential to bind and infect HIV-1 receptor CD4-positive cells but also to CD4-negative-SARS-CoV-2 receptor ACE2-positive cells that are widely distributed in the peripheral vascular and the central nervous system. This perspective raises concerns about these realistic possibilities that need to be scientifically addressed and evaluated in COVID-19 mRNA vaccine recipients infected with retroviruses, including those who are at high risk of acquiring new retroviral infections.
See publicationExternal link
Dhawan, S. Therapeutic potential of inducible endogenous cytoprotective heme oxygenase-1 in mitigating SARS-CoV-2 infection and associated inflammation. Antioxidants 2022, 11: 662.
MDPI March 30, 2022

ABSTRACT: The inducible cytoprotective enzyme heme oxygenase-1 (HO-1) has gained significant recognition in recent years for mediating strong cellular resistance to a broad range of viral infections, regardless of the type of viruses, viral strains, or mutants. HO-1 is not a typical antiviral agent that targets any particular pathogen. It is a “viral tropism independent” endogenous host defense factor that upon induction provides general cellular protection against pathogens. By virtue of HO-1…
See publicationExternal link
Dhawan, S. Simple and economical multifunctional therapeutic swab device system for treating upper respiratory infections, including SARS-CoV-2, on a mass-scale. Am. Pharma. Rev. 2022, 25: 20-24. [March 2022 issue; U.S. and PCT Patent Pending].
American Pharmaceutical Review March 24, 2022

ABSTRACT: New tools are urgently needed to control the current out-of-control COVID-19 pandemic which can be further complicated by annually emerging influenza infections, especially in the winter months. This article offers a simple and economical Therapeutic Swab Device System comprising multifunctional drugs for their direct application to nasal cavity, oral cavity, nasopharynx and posterior pharynx that are the primary sites of upper respiratory infection, including SARS- CoV-2. This system…
See publicationExternal link
Huang. H. et al. Hemin activation abrogates Mycoplasma hyorhinis replication in chronically infected prostate cancer cells via heme oxygenase-1 induction. FEBS Open Bio. 2021, 11:2727-2739.
Wiley August 10, 2021

ABSTRACT: Mycoplasma hyorhinis (M. hyorhinis) lacks a cell wall and resists multiple antibiotics. We describe here the striking > 90% inhibitory effect of hemin, a natural inducer of the cytoprotective enzyme heme oxygenase-1 (HO-1), on M. hyorhinis replication in chronically infected LNCaP prostate cancer cells. The role of HO-1 in interrupting M. hyorhinis replication was confirmed by HO-1-specific siRNA suppression of hemin-induced HO-1 protein expression, which increased intracellular M.…
See publicationExternal link
Dhawan S. Significance of innate immunity in mitigating SARS-CoV-2 infection. Am. Pharma. Rev. 2021, 24:48-49, 2021.
American Pharmaceutical Review June 18, 2021

ABSTRACT: Continuously surging numbers of global COVID-19 cases caused by rapidly emerging SARS-CoV-2 mutants forming more contagious and deadly viral strains force our scientific capacity to find creative ways to control the pandemic. While current SARS-CoV-2 vaccines are quite effective in reducing the severity of the disease, hospitalization and deaths, none is yet known to provide complete protection from acquiring SARS-CoV-2 infections and to prevent reinfections of the recovered adults or…
See publicationExternal link
Dhawan S. Innate cellular immunity for suppressing viral infections. Curr. Trends Immunol. 2021, 22: 19-21.
Research Trends

ABSTRACT: Innate immunity is our first-line, generic/non-specific host defense mechanism against viral infections, regardless of the type of virus. This component of anti-viral immunology could potentially provide initial protection of host cells against viral infections, but it is generally overlooked as a potential candidate for pharmacological enhancement. Although immunization against individual pathogens provides protection against specific infections and reduces disease severity, the…
See publicationExternal link
Dhawan S. Necessity for the evaluation of stimulated cellular immunity against SARS-CoV-2 infection. Curr. Trends Immunol. 2021, 22: 43-47, 2021
Research Trends

ABSTRACT: Innate immunity is the first-line of non-specific host defense mechanism against pathogens, regardless of the type of strains and mutants. This pivotal component of viral immunology, extremely critical for protecting host cells against infections, has largely been overlooked for SARS-CoV-2 infection. While effective immunization against SARS-CoV-2 reduces the severity of the disease, constantly emerging viral mutants and variant strains continue to pose difficult challenges for…

See publicationExternal link
These are most recent publications
-

Patents

"Therapeutic swabs for treating upper respiratory infections" (U.S. and PCT Patent Pending, 2021). Sole Inventor - Subhash Dhawan
Filed August 31, 202117462070

The present invention offers a Therapeutic Swabs Device System as the first therapeutic approach intended to deliver plurality of antiviral, antimicrobial, cytoprotective, anti-inflammatory, and low- or non-anticoagulant drugs to the nasal and oral cavities, nasopharynx, and posterior pharynx, the primary sites of upper respiratory infections. This invention enables an ideal multiprong therapeutic approach for effective targeting of serious upper respiratory infections in humans and in…

Projects

Independent scientific writer • Provides guidance on research and regulatory projects related to in vitro diagnostics, vaccines, and therapeutics • Provides scientific editorial assistance • Amateur self-taught keyboard player
-

More activity by Subhash

#covid #inflammation #resolution #HeatShockResponse Chronic suppression of the physiological #resolution of #inflammation via heat shock proteins…
#covid #inflammation #resolution #HeatShockResponse Chronic suppression of the physiological #resolution of #inflammation via heat shock proteins…
Liked by Subhash Dhawan
January 23, 2023 REPOSTING MY COMMENTS ON Lori Peterson's VERY IMPORTANT LinkedIn POST TWO OR MORE WEEKS AGO. My apologies Dr. Amesh Adalja, but I…
January 23, 2023 REPOSTING MY COMMENTS ON Lori Peterson's VERY IMPORTANT LinkedIn POST TWO OR MORE WEEKS AGO. My apologies Dr. Amesh Adalja, but I…
Shared by Subhash Dhawan
I have mentioned the AI Frame Problem previously. This is a great demonstration of it. The dad is AI, the kids are just plain old I. I programing…

Your intuition was correct there most likely is a connection:

Subhash Dwawan...now retired

Viral immunologist with a Ph.D. in biomedical research and more than 25 years of experience with the United States Food and Drug Administration (FDA) regulatory processes. Served as a Principal Investigator and Chief of the Viral Immunology Section to direct and manage an independent research program involving infections: HIV-1, Ebola virus, West Nile virus, Zika virus, and mycoplasma. Actively participated in the FDA review process of 510(k), IDE, IND, and BLA submissions related to in vitro diagnostics, and conducted several US and foreign pre-approval/pre-licensure inspections of manufacturing facilities. Chaired or served as a member on several internal FDA regulatory committees, represented FDA as an ad hoc external committee member for developing guidance for diagnosis and monitoring of infectious diseases, and presented invited and keynote addresses at domestic and international conferences.

See page 2 section 0032

"An embodiment of the present invention relates to utility of brilacidin, a peptide or a biomimetic antimicrobial polymer derived from a host protein defensin exhibiting antiviral and antibacterial activities."

Quite clever. What will they think up next?

Think of the lives that could be saved. I will join you in praying for its success.

GLTA,
Farrell

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20230036304

IPIX's scientific adviser, William DeGrado Phd, is finding success with a company he helped develop, Pliant Pharmaceuticals. Dr DeGrado is one of the world leading researchers on protein science. He performed some of the basic research on Pliant's new drug for pulmonary fibrosis which recently reported a successful mid phase clinical trial.

More details below:

https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-announces-positive-data-integris-ipf-phase

https://finance.yahoo.com/news/pliant-therapeutics-plrx-surges-44-152103262.html

https://ir.pliantrx.com/press-releases

https://pliantrx.com/scientific-founders/

Good luck,
Farrell

Good to hear the progress in SW African oil fields.Thanks for posting.

Farrell

Not so strange articles regarding the Kevetrin's P53 modulating properties against malignancies:

https://pubmed.ncbi.nlm.nih.gov/32945487/

Kumar A, Hiran T, Holden SA, Chafai-Fadela K, Rogers S, Ram S, Menon K. Kevetrin™, a novel small molecule, activates p53, enhances expression of p21, induces cell cycle arrest and apoptosis in a human cancer cell line. Cancer Res. 2011;71:4470.

Kumar A, Holden SA, Chafai-Fadela K, Ram S, Menon KE. Kevetrin targets both MDM2-p53 and Rb-E2F pathways in tumor suppression. Cancer Res. 2012;72:2874

Kumar A, Brennan DP, Chafai-Fadela K, Holden SA, Ram S, Shapiro GI, Menon GI. Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies. Cancer Res. 2017;77:322.

Shapiro G, Supko JG, Cho DC, Hilton JF, Hadfield M, Pruitt-Thompson S, Bordoli-Trachsela E, Zvereva N, Wolanski A, Sato-DiLorenzo A, et al. A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors. J Clin Oncol. 2013;31(Suppl 15):TPS2627. doi: 10.1200/jco.2013.31.15_suppl.tps2627. - DOI

https://www.annalsofoncology.org/article/S0923-7534(19)34531-4/fulltext#back-bb0215

GLTA, Farrell

From Basilea Pharmaceuticals 5/22/2022

It appears Brilacidin is on Basileas radar as an antibiotic. The new Brilacidin antifungal findings should only make Basilea more interested.

JMO

GLTA, Farrell

https://www.edisongroup.com/publication/renewed-focus-on-anti-infectives/30855/

"To increase focus and momentum in the anti-infective pipeline we expect Basilea to actively engage in licensing and/or transaction deals for further clinical-stage, anti-infective assets. Here, we envisage the company proceeding with licensing or the outright purchase of assets that are indicated against resistant bacteria/fungi and/or in Phase II or III and/or possess a novel mechanism of action. Examples of such assets are displayed in Exhibit 9. We note that these are examples that fit the above criteria but are however not to our knowledge current acquisition or licensing targets for Basilea.

Exhibit 9: Anti-infective assets currently in development

Asset


Company


Indication


Drug class


MOA


Market status

Afabicin


Debiopharm


ABSSSI, bone and joint infections


Benzofuran naphthyridine


Fatty acid synthesis inhibitor


Phase II

Brilacidin (iv)


Innovation Pharmaceuticals


MRSA infections, gram-negative infections.


Defensin mimetic


Host Defence Protein (HDP) regulator


Phase II

CRS3123


Crestone Inc.


Clostridium difficile infection


Diaryldiamine


Methionyl-tRNA synthetase inhibitor


Phase II

Zoliflodacin


Entasis Therapeutics


Gonorrhoea


Spiropyrimidinetrione


type II topoisomerase inhibitor


Phase III

Olorofim


F2G


Invasive aspergillosis
Coccidioidomycosis
Invasive moulds


Orotomide


dihydroorotate dehydrogenase inhibitor


Phase II

Source: Edison Investment Research, Evaluate Pharma

With the anticipated divestment of the oncology pipeline during CY22, we see deals of this kind as a potential near/mid-term value driver for Basilea, considering its experience in the area."

Trago Energy, Namibian Affiliate of Sintana, Completes Transaction in Respect to Its Interests in PEL 90
10:57 am ET October 4, 2022 (Globe Newswire) Print
GlobeNewswireOctober 04, 2022

TORONTO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Sintana Energy Inc. (TSX-V:SEI) (OTCQB:SEUSF) ("Sintana" or the "Company") is pleased to announce that Trago Energy (Pty) Limited ("Trago"), a Namibian affiliate of the Company, has completed a transaction (the "Transaction") with Chevron Namibia Exploration Limited, a wholly-owned subsidiary of Chevron, in respect of its interest in Petroleum Exploration License 90 ("PEL 90") located in the Orange Basin in Namibia.

Trago will retain a 10% interest in PEL 90 ON Block 2813B. Chevron will carry Trago through initial exploration activities including 3D seismic and drilling of the first exploration well. Post the carry period, Trago will be responsible with approved expenses associated with its interest. Additional terms of the transaction have not been publicly disclosed.

PEL 90 represents one of the most exciting exploration opportunities in the Orange Basin sitting directly above TotalEnergies' Venus-1 oil discovery.

"We are very happy to partner with Chevron in the Orange Basin," said Knowledge Katti, Chairman and CEO of Trago and a Director of Sintana. "This transaction in our emerging, globally significant deepwater province brings partnership with an aligned, highly experienced and committed deep water drilling operator.

"This partnership demonstrates the continuing emergence of Namibia as an important hydrocarbon province, and the timeliness of our entry in March of this year," said Robert Bose, President and Director of Sintana. "We look forward to the near-term exploration activity on PEL 90."

ABOUT SINTANA ENERGY:

The Company is engaged in petroleum and natural gas exploration and development activities in Colombia's Magdalena Basin and five large, highly prospective, onshore and offshore petroleum exploration licenses in Namibia. Sintana's exploration strategy is to acquire, explore, develop and produce superior quality assets with substantial reserves potential.

On behalf of Sintana Energy Inc.,

Great news. Chevron to partner with Sintana in Orange basin PEL 90.

Trago Energy, Namibian Affiliate of Sintana, Completes Transaction in Respect to Its Interests in PEL 90
10:57 am ET October 4, 2022 (Globe Newswire) Print
GlobeNewswireOctober 04, 2022

TORONTO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Sintana Energy Inc. (TSX-V:SEI) (OTCQB:SEUSF) ("Sintana" or the "Company") is pleased to announce that Trago Energy (Pty) Limited ("Trago"), a Namibian affiliate of the Company, has completed a transaction (the "Transaction") with Chevron Namibia Exploration Limited, a wholly-owned subsidiary of Chevron, in respect of its interest in Petroleum Exploration License 90 ("PEL 90") located in the Orange Basin in Namibia.

Trago will retain a 10% interest in PEL 90 ON Block 2813B. Chevron will carry Trago through initial exploration activities including 3D seismic and drilling of the first exploration well. Post the carry period, Trago will be responsible with approved expenses associated with its interest. Additional terms of the transaction have not been publicly disclosed.

PEL 90 represents one of the most exciting exploration opportunities in the Orange Basin sitting directly above TotalEnergies' Venus-1 oil discovery.

"We are very happy to partner with Chevron in the Orange Basin," said Knowledge Katti, Chairman and CEO of Trago and a Director of Sintana. "This transaction in our emerging, globally significant deepwater province brings partnership with an aligned, highly experienced and committed deep water drilling operator.

"This partnership demonstrates the continuing emergence of Namibia as an important hydrocarbon province, and the timeliness of our entry in March of this year," said Robert Bose, President and Director of Sintana. "We look forward to the near-term exploration activity on PEL 90."

ABOUT SINTANA ENERGY:

The Company is engaged in petroleum and natural gas exploration and development activities in Colombia's Magdalena Basin and five large, highly prospective, onshore and offshore petroleum exploration licenses in Namibia. Sintana's exploration strategy is to acquire, explore, develop and produce superior quality assets with substantial reserves potential.

On behalf of Sintana Energy Inc.,

Sorry to ruffle your feathers. I just posted the article to add context to the previously posted article.

Farrell

In return [For a 1 year extension of the EEZ drilling contract} the oil companies [Total and Angol }agreed to plough an additional $250,000 into social programs [in STP].

https://www.upstreamonline.com/exploration/totalenergies-lands-licence-extension-offshore-sao-tome-principe-as-shell-eyes-wildcat/2-1-1076338

Farrell

Beautiful review.

Should be stickied; Moderators?

GLTA Farre

TPOOX.tecovirimat the only drug approved for smallpox seems to be the only other antiviral being studied for monkeypox besides Brilacidin.

The FDA is looking at very few options for treating the current viral epidemic of monkey pox as welll as other viral disorders.

https://clinicaltrials.gov/ct2/results?cond=monkeypox&term=&cntry=&state=&city=&dist=

https://www.niaid.nih.gov/diseases-conditions/monkeypox-treatment

Good luck,

Farrell

Sintana's deal for the Namibian assets could be very lucrative if drilling confirms its oil and gas potential.

For 5.7 million dollars Sintana obtained 49% of Inter oil:

Interoil assets

" (i) a 15% carried interest in PEL 87; (ii) a 10% carried interest in each of PELs 82 and 83; and (iii) a 20% carried interest in PEL 90."

" In addition, the completion of the Acquisition is contingent upon the grant of a 90% interest in onshore Block 1918B to an indirect subsidiary of Inter Oil, of which the Company will acquire an indirect 30% interest." { The contingent event described has been completed}

"Three of the four offshore PELs to be acquired are located directly outboard of (i) the Kudu Gas Field, which was the first offshore discovery in Namibia; (ii) Venus-1, a highly anticipated exploration well immediately south of PEL 90, which is proposed to be drilled by French supermajor Total in the fourth quarter of 2021, and (iii) Graff-1, a highly anticipated exploration well immediately south of PEL 83, which is to be drilled by Shell. In addition, Block 1918B is located in close proximity to the prospective block currently being evaluated by Reconnaissance Energy Africa Ltd."

https://www.yahoo.com/now/sintana-announces-execution-definitive-agreement-170900488.html

In addition Interoil's president will assume a board seat on Sintana's BOD

" In connection with the closing of the acquisition, Knowledge Katti has been appointed to the board of directors of Sintana. "

https://www.marketscreener.com/quote/stock/SINTANA-ENERGY-INC-49478488/news/Sintana-Energy-Inc-acquired-49-stake-in-Inter-Oil-Ltd-from-Grisham-Assets-Corp-for-5-7-million-39709855/

Good luck,

Farrell

Correction Brilacidin for OM dose was 45mg/15cc tid

Farrell

Is the ulcerated oral mucosa that different from an ulcerated sigmoid colon?

The oral mucosa does have less surface area than the sigmoid colon ;so based on surface area brilacidin's absorption should be higher through the colon.

The dosage is in the ulcerative colitis study was 200mg while in the oral mucositis study it was only 3mmg per 5cc.So the absorption should be higher in the UC study

In addition the UC patients were given Brilacidin as a retention enema as opposed to the swish and spit BOM study. The time of contact to the mucosa would be much higher in the UC study.

Yet the UC study showed almost no systemic absorption, nanograms.
Just a reminder 1 billion nanograms are in a gram

" Brilacidin was generally well-tolerated and patients maintained stable normal vital signs during treatment..

Measurements of drug concentrations in plasma continued to show limited systemic absorption of Brilacidin, with all values registering less than 100 ng/mL for all six patients in Cohort A and averaging approximately 200 ng/mL maximum concentrations... "

https://www.globenewswire.com/news-release/2017/03/08/933305/0/en/Cellceutix-Releases-Preliminary-Efficacy-and-Safety-Data-in-Interim-Analysis-of-First-Two-Cohorts-in-Phase-2-Trial-of-Brilacidin-for-the-Induction-of-Remission-of-Mild-to-Moderate-.html

When a company is doing its due diligence to partner with IPIX , do you think they will look at actual numbers ?

Indeed !

GLTA,Farrell

Of course, you could be right, but its more likely any associated morbidity is due to the chemotherapy , radiation, cancer, poor nutrition, dehydration, electrolyte imbalances and other complications of the cancer and its treatment ...as well as the the oral mucositis.

Besides, we all know Brilacidin is not absorbed systemically.

Try again

GLTA,
Farrell

It has been widely reported that the Soviet Union has developed the ability to dispense Marburg virus from missiles.

Another reason to develop Brilacidin as an antiviral.

https://www.globalsecurity.org/wmd/intro/bio-marburg.htm

In the 1980s, the Soviet Union experimented with the Marburg virus in aerosol form on monkeys and determined that infection required only a few virions. Ken Alibek (formerly Kanatjan Alikbekov) who secretly immigrated to the United States in 1992 revealed information about Soviet experimentation with the Marburg virus. The former First Deputy Director of Biopreparat, the Soviet biological weapons program, Dr. Alibek reported that Soviet scientists were researching whether Marburg could be loaded into a warhead or a MIRV delivery system.

GLTA Farrell

Interesting review of the economics of the Jaca well

https://ihsmarkit.com/research-analysis/can-jaca-turn-sao-tome-and-principe-into-new-oil-producer-with.html

GLTA,Farrell

It is unlikely the Russians will end oil supplies to Europe. I agree with JP Morgan a more likely scenario is for the Russians to reduce production globally. No one has the excess capacity to counter Russian oil cuts of several million barrels...not even OPEC.

Meanwhile the US restricts the release of drilling leases.

https://www.bloomberg.com/news/articles/2022-07-01/jpmorgan-sees-stratospheric-380-oil-on-worst-case-russian-cut

GLTA Farrell

Thanks for copying and posting the purchase of IPIX preferred stock and warrants by Kips Bay.

As you pointed out it was a good deal for Kips Bay with little incentive to hold them any longer than the restrictions listed in the terms of the sale.

The questions now are when did Kips Bay convert the preferred to commons shares and when did they sell the common shares and warrants.

Unless you know the above you can not know if the increase Kips Bay holding is a purchase or conversion of preferred shares. While I have not been able to determine the time of conversion of the preferred or the sale of the commons shares and warrants Kips Bay reporting does give clues.

Kips bay reported owning 4.97% [21.2 million} IPIX common shares 0n 5/3/21.

https://sec.report/Document/0001213900-21-024168/

On 7/5/2022 Kips Bay reported owning 9.9% [45 million} of IPIX common shares.

https://sec.report/Document/0001213900-22-037187/

Investopedia confirms common and preferred shares are included in ownership calculations.

It appears there is more evidence for a 23 million share stock purchase by Kips Bay rather than a conversion of preferred shares.

Good luck,Farrell

Innovation Pharmaceuticals Inc. Common Stock (QB)

$0.0485 0.01 (52.03%)
Bid/Ask
0.043 / 0.0485
Volume
1,084,222

Up 52% I am looking forward to more good news.

GLTA,Farrell

Impact Oil & Gas prepares to sell stake in Namibian offshore block

LONDON, June 6 (Reuters) - Impact Oil & Gas is considering selling its 20% stake in a large block in deep water off the coast of Namibia where TotalEnergies (TTEF.PA) made a significant oil discovery this year, four industry sources told Reuters.

Impact, which is privately owned and focused on exploration in Africa, has hired investment bank Jefferies to prepare a sale process for its stake in Block 2913B, which is estimated to be worth $500 million to $1 billion, the sources said.

https://www.reuters.com/markets/europe/impact-oil-gas-prepares-sell-stake-namibian-offshore-block-sources-2022-06-06/

GLTA, Farrell

Squalus, IPIX's partner, is planning to have the new system evaluated by the FDA 510k path.

IMO the system is likely to use a laser already approved for human treatment, since the PR did not mention a new laser.

In addition laser treatments have been performed for a number of years for all the indications indicated in the PR, epilepsy and tumors of the brain, lung,prostate,breast and liver.

The Squalus laser system may be viewed by the FDA primarily as an imaging and software change to better direct the laser treatment and as such may require a much shorter path to the 510k approval.

Investors will have to wait until these points are clarified by the FDA and Squalus.

https://www.fda.gov/media/99785/download

The quote below does not apply to the Squalus system since it is applying for the 510k designation. It is placed here to show software changes are held to a different level of scrutiny.

"Many software functions are not medical devices (meaning such software functions do not meet the definition of a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)), and FDA does not regulate them as devices."

https://www.fda.gov/media/80958/download

Good luck, Farrell

A better way to link article:

https://www.sciencedirect.com/science/article/abs/pii/S0960894X20308386?via%3Dihub

Click box at top...View Open Manuscript

GLTA, Farrell

A drug library [? HDP antifungals discovered by Polymedix} was screened for antifungal activity. in this 2017 report. One of these drugs,C4. was studied for effects against Canidia albicans. and was found to have "potent" anti fungal effects

Note disclosure at end of article:

"Dr. Scott owns stock in Cellceutix, Inc., which owns the patent on compound C4."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489528/

GLTA,

Fareell

Dr Scott's publication of antifungal research seems to be an extension of the Polymedics HDP development program,

"We have developed a series of non-peptide analogs of the host defense proteins (HDP mimics,
smHDPs) as antimicrobial agents that have distinct advantages over peptides for pharmaceutical use
[16, 17]. The overarching goal of our approach is to recapitulate the biological and structural properties
of HDPs into oligomeric backbones without trying to duplicate the dimensional structures of the
peptides but rather by creating small structurally constrained cationic compounds. These smHDPs have
better pharmacokinetic and tissue distribution properties than peptidic HDPs due to their smaller size
and improved stability; and are less expensive to prepare with the selection of appropriate building
blocks. Furthermore, synthetic chemistry, expanded beyond amino acids, provides considerably more
chemical space to fine-tune structures for enhanced antimicrobial activities and minimized toxicity."

Note reference #16 and 17

JMO,

Farrell

https://pdf.sciencedirectassets.com/271398/1-s2.0-S0960894X20X00254/1-s2.0-S0960894X20308386/am.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEGkaCXVzLWVhc3QtMSJIMEYCIQC1iZtNywpl%252FQXVFfkGhOHr8wc%252Bsbq%252BedTQfgdsaVI21wIhALTNuyCSKA0ShgjxIb55S3nq9pdrVr%252BVkp7cXaTvAcy%252FKtIECGIQBBoMMDU5MDAzNTQ2ODY1IgwJF%252FKKusKtL%252FN%252BcakqrwRQa3smHiGckr5qIPzBVYYwZmNUuHmG4D23MW4Gvn1luWcDPww81ugv4eABN0g3XMsqrIOC5v7qiXN33s54Hj2HVZTGk5bEImaEupIsQDe9meNFuNwIjww%252FlH7AmdmAxvIdjJMqZgcpUggVTKb7LvK6CVcxc9QMo%252FKmq0Mxi3Dfpnoi1DPnZPCZvwiumf1%252B6MkoBIByXMvpa7OI74%252F7CHsRaQpWu%252BYs5pYQaZR%252Br6LYzR3b85BZ3Efs70L1ZIoGpXZYUb9OsLTlie2qmNmuNjJlp5wIdfsLafdBqbpEr7%252FIfBkTYsqdyyYvDIXSvWO2Jp6FqP4BnoxQg%252B9CcGpcri2ldGDnqNzJ7peAlD93EQPLTUHA4REl455BRpW%252FsEz%252FoYZmVFLw%252FDsTvg6gLjDILUGZFq20UtY7MO32EDvpZQkZ6Fxh6wBOiruLYhE9sQqyB6vPM6FNBu%252F3giacyf5tykXIJGI08qNdRkXUfRVon5YYn%252BRGxVj3oyA8ZC%252F%252FSPQCdFih79hNRz%252B0Uh%252BUVFQwllsbwhO7tmAdGnHfswcdQQReqsKW3Q4lBukxe%252FS9%252FWcWkkHQ2MRZHufGJ%252F1mVwvHCMj6D3M%252Fzpc9nhfJ79BVY%252BjByO0zrHnL9ku80ApKJ2V1ygovl83Cnd2%252FmNccpBBLBeqjMNu8HHmKT9fFtSeP3sQlQFvEpqtQby4NGMGXiSvawS%252BeSwI6Qf6X7efcOcXYQD27ZG0c16uBi6DBHn0vpId9MMDX45QGOqgBgcVZb7vdaJC7chP5sLBhqLwUCqD7sBNX4fdL%252FYvYjsh33GgvBCPNJlA%252BtpDVG5BeYuN6ssdfKPdH2lbkx7Q4oiloyncR%252BOPwSwn7F9O7qImFY5q8dix%252Bmwpk%252BtDvcX74Dsd%252Fjb76xNsRgZ%252FqdwMZyuHvnasHuU4KAMeK5w6yYtlzyaSg7ymK90QUSLlA1oaym0HWzJRipOEeWDpZvafSoJ3b21CurNKa&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20220602T175927Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYWRRMRMEN%252F20220602%252Fus-east-1%252Fs3%252Faws4_request&X-Amz-Signature=922490a70f254a920cd37c57d4e544ca643d9a66fec5df042127a5057f07f70

AOIFF owns 6% through Impact oil.

"AOI) (Africa Oil Corp. ("AOI", "Africa Oil" or "the Company") is pleased to note the press release by TotalEnergies, the operator of Block 2913B, offshore Namibia. Africa Oil has an indirect interest in this block through a 30.9% shareholding in its investee company Impact Oil & Gas Limited ("Impact") with a 20% working interest in the block."

https://www.yahoo.com/now/africa-oil-announces-major-light-083000464.html

GLTA,
Farrell

Plus ERHC may claim its 15% of 2 EEZ blocks ...

"ERHC will decide whether to take up the option to acquire up to a 15% paid working interest in each of two additional blocks of the EEZ when called upon to exercise the option by the Government of STP in accordance with the agreements which provide for the rights and option."

Farrell

Big buys into close. Last trade at .044

Unusual activity as last trades of week.

News pending ??? Or more jerking around???

Time will tell.

GLTA Farrell

Today in Upstream: Africa Oil eyes wildcat on red-hot Orange basin block in South Africa

Deepwater Block 3B/4B could host 3 bn barrels of oil and 1.5 Tcf of gas in just three prospects.

GLTA,Farrell